We will help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.
EXACT SCIENCES 1
Colon cancer screening
Molecular residual disease
Multi-cancer screening
$18B TAM $15B TAM $25B TAM
cologuard plusTM oncodetectTM cancerguardTMlaunched March 2025 launched April 2025 launching 2H25
Source: Exact Sciences estimates, U.S. markets only;
Exact Sciences is preparing for the commercialization of Cancerguard
EXACT SCIENCES
EXACT SCIENCES 3
Exact Sciences is a global leader in advanced cancer diagnostics with a differentiated platform
OUR FOOTPRINT OUR IMPACT & SCALE OUR CAPABILITIES
7,000+team members
~200Kordering providers each quarter
9R&D centers and labs
4.6Mtest results in 2024
$2.76Btotal revenue in 2024, up 10% Y/Y
$323Madjusted EBITDA in 2024, up 48% YY
Proprietary scientific platform
detects cancer earlier and accurately
Powerful commercial engine, deep relationships, broad platform
Unrivaled ExactNexusTM tech platform enabling connectivity across healthcare
Please refer to the appendix accompanying this presentation for discussion of non-GAAP financial measures and reconciliations to GAAP financial measures.
The Exact Sciences platform enables sustainable revenue growth and profitability improvement over timeGrow revenue and profits
to fuel our mission
Invest in world-class talent dedicated to fighting
cancer
Offer tests that impact decision-making
Expand and leverage our platform
Generate rock-solid clinical evidence
Increase access & drive adoption
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |
Attachments
- Original document
- Permalink
Disclaimer
EXACT Sciences Corporation published this content on May 15, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 16, 2025 at 12:55 UTC.
